pomalidomide NDC 43598-520

NDC codes

FDA NDC Directory

Product NDC (as listed)43598-520Labeler and product segments. Claims need a package NDC.

Product NDC at billing width43598-0520Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
43598-520-01	43598052001	100 CAPSULE in 1 BOTTLE (43598-520-01)Marketed from Aug 31, 2026
43598-520-21	43598052021	21 CAPSULE in 1 BOTTLE (43598-520-21)Marketed from Aug 31, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): pomalidomide
Generic name (nonproprietary): pomalidomide
Active ingredients: Pomalidomide — 1 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Dr. Reddy's Laboratories Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213234
Marketing start: Aug 31, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 43598-520_b991ba5e-18e6-8b03-22f1-e409f4db8cccSPL ID b991ba5e-18e6-8b03-22f1-e409f4db8cccSPL set ID 84678d19-fd8d-268e-2fe6-88e21195fccaRxCUI 1369718, 1369726, 1369730, 1369734UNII D2UX06XLB5UPC 0343598518213, 0343598517216, 0343598520216, 0343598519210
Pharmacologic class: Thalidomide Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N443598052001 followed by a unit qualifier and the quantity

Package 43598-0520-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 6, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Pomalidomide is a thalidomide analogue indicated, for the treatment of adult patients: in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213234

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213234
Product	Strength	Form · route	Labeler	Product NDC
pomalidomide	Pomalidomide 4 mg/1	CapsuleOral	Dr. Reddy's Laboratories Inc.	43598-517
pomalidomide	Pomalidomide 3 mg/1	CapsuleOral	Dr. Reddy's Laboratories Inc.	43598-518
pomalidomide	Pomalidomide 2 mg/1	CapsuleOral	Dr. Reddy's Laboratories Inc.	43598-519